Pharming Group (NASDAQ:PHAR - Get Free Report)'s share price gapped down prior to trading on Wednesday . The stock had previously closed at $9.25, but opened at $8.95. Pharming Group shares last traded at $8.95, with a volume of 1,342 shares trading hands.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the company. Jefferies Financial Group assumed coverage on Pharming Group in a report on Monday, December 9th. They issued a "buy" rating and a $14.00 price objective for the company. HC Wainwright reissued a "buy" rating and issued a $37.00 price objective on shares of Pharming Group in a report on Tuesday, December 17th.
Read Our Latest Stock Analysis on PHAR
Pharming Group Trading Down 3.8 %
The firm has a market cap of $547.65 million, a P/E ratio of -30.96 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The firm has a fifty day moving average of $9.17 and a 200-day moving average of $8.57.
Hedge Funds Weigh In On Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 47,997 shares of the company's stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 0.03% of the company's stock.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
